US Is Loading Up on Bird Flu Vaccine
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply
The companies will use the funds to fill vials and pre-filled syringes with stockpiled vaccine ingredients, aimed at raising the country’s total supply of ready-to-use doses to 10 million within the f
GSK, Sanofi, CSL said to win $72M U.S. bird flu vaccine contract (update)
Sanofi (SNY), and CSL (CSLLY) win $72M U.S. contract to expand bird flu vaccine production amid fears of human transmission. Read more here.
GSK, Sanofi, CSL nab $72M in BARDA funding to boost bird flu vaccine supply
CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. | CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5 cases.
US provides $72M to vaccine manufacturers to advance bird flu shot preparedness
There are currently no recommendations for anyone to be vaccinated against bird flu and federal health officials note this is being done out of "an abundance of caution."
The US Is Loading Up on Bird Flu Vaccine
As more farm workers get sick with avian influenza, the US federal government is putting $72 million toward strengthening its vaccine stockpile.
US allocates $72M to CSL, GSK, Sanofi for bird flu vaccine production
US has announced team up with multinational pharmaceutical companies CSL, GSK, Sanofi, and Seqirus for a $72 million worth of bird flu vaccine production initiative.On Friday, October 4, the US Federal health officials announced that they will
BAR­DA doles out $72M to Sanofi, GSK and CSL for bird flu vac­cine sup­ply
The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to help fortify the US supply of bird flu vaccine ahead of 2025. The funding was disclosed by the Administration for Strategic Preparedness and Response,
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine ...
PharmiWeb1d
GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024
New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...
GlobalData on MSN6d
GSK reports positive findings from Phase III RSV vaccine trial
The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...
kffhealthnews6d
GSK’s Widely Used RSV Shot Retains 43% Potency In Third Year, Data Show
Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...